
Invitae Corporation NVTA
Quarterly report 2023-Q3
added 11-08-2023
Invitae Corporation Accounts Payables 2011-2026 | NVTA
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Invitae Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 14 M | 21.1 M | 25.2 M | 10.3 M | 7.81 M | 8.61 M | 3.35 M | 3.5 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 25.2 M | 3.35 M | 11.7 M |
Quarterly Accounts Payables Invitae Corporation
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25.2 M | 23.1 M | 11.9 M | 14 M | 10.7 M | 26.8 M | 41.7 M | 21.1 M | 35.4 M | 31.2 M | 39 M | 25.2 M | 25.2 M | 25.2 M | 25.2 M | 10.3 M | 10.3 M | 10.3 M | 10.3 M | 7.81 M | 7.81 M | 7.81 M | 7.81 M | 8.61 M | 8.61 M | 8.61 M | 8.61 M | 3.35 M | 3.35 M | 3.35 M | 3.35 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 2.86 M | 2.86 M | 2.86 M | 2.86 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 41.7 M | 2.86 M | 13.5 M |
Accounts Payables of other stocks in the Diagnostics research industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
36.6 M | - | -17.87 % | $ 25.9 M | ||
|
Chembio Diagnostics
CEMI
|
3.34 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
952 K | - | - | $ 9.42 M | ||
|
Burning Rock Biotech Limited
BNR
|
63.1 M | $ 23.41 | 0.47 % | $ 252 M | ||
|
Biocept
BIOC
|
1.52 M | - | -13.05 % | $ 7.29 M | ||
|
Castle Biosciences
CSTL
|
6.9 M | $ 39.7 | 0.92 % | $ 1.1 B | ||
|
Co-Diagnostics
CODX
|
1.48 M | $ 6.0 | -3.07 % | $ 176 M | ||
|
Accelerate Diagnostics
AXDX
|
4.5 M | - | -61.36 % | $ 2.46 M | ||
|
DermTech
DMTK
|
1.48 M | - | -11.32 % | $ 2.94 M | ||
|
DexCom
DXCM
|
276 M | $ 70.68 | 4.87 % | $ 27.3 B | ||
|
BioNano Genomics
BNGO
|
6.96 M | $ 1.58 | - | $ 2.01 M | ||
|
Guardant Health
GH
|
38.6 M | $ 107.76 | -2.19 % | $ 13.2 B | ||
|
Global Cord Blood Corporation
CO
|
8.33 M | - | - | $ 399 M | ||
|
Illumina
ILMN
|
221 M | $ 145.25 | 2.96 % | $ 23.1 B | ||
|
IQVIA Holdings
IQV
|
322 M | $ 241.11 | -0.55 % | $ 43.7 B | ||
|
CareDx, Inc
CDNA
|
12.9 M | $ 20.41 | 19.15 % | $ 1.1 B | ||
|
Danaher Corporation
DHR
|
1.75 B | $ 238.83 | 0.2 % | $ 175 B | ||
|
Celcuity
CELC
|
9.37 M | $ 104.34 | -2.95 % | $ 4.12 B | ||
|
DarioHealth Corp.
DRIO
|
1.13 M | $ 11.97 | -1.56 % | $ 340 M | ||
|
Anixa Biosciences
ANIX
|
165 K | $ 3.19 | -5.62 % | $ 102 K | ||
|
Enzo Biochem
ENZ
|
1.38 M | - | -8.98 % | $ 14.8 K | ||
|
Lantheus Holdings
LNTH
|
34.6 M | $ 67.28 | -0.41 % | $ 4.66 B | ||
|
Exact Sciences Corporation
EXAS
|
89.6 M | $ 102.23 | 0.11 % | $ 18.9 B | ||
|
Fulgent Genetics
FLGT
|
18.4 M | $ 28.16 | 1.11 % | $ 851 M | ||
|
Medpace Holdings
MEDP
|
32.5 M | $ 599.7 | 0.79 % | $ 18.6 B | ||
|
Aspira Women's Health
AWH
|
881 K | - | -6.19 % | $ 10.5 M | ||
|
Myriad Genetics
MYGN
|
32.3 M | $ 6.56 | -0.3 % | $ 594 M | ||
|
Charles River Laboratories International
CRL
|
140 M | $ 219.73 | -0.62 % | $ 11.3 B | ||
|
Heska Corporation
HSKA
|
16.4 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
1.16 M | - | -20.0 % | $ 1.06 M | ||
|
National Research Corporation
NRC
|
1.3 M | $ 20.3 | 2.94 % | $ 498 M | ||
|
Mettler-Toledo International
MTD
|
216 M | $ 1 486.95 | 0.1 % | $ 31.6 B | ||
|
Natera
NTRA
|
31.1 M | $ 233.65 | -0.28 % | $ 23 B | ||
|
ENDRA Life Sciences
NDRA
|
270 K | $ 4.51 | -3.01 % | $ 2.42 M | ||
|
Neogen Corporation
NEOG
|
79.6 M | $ 9.33 | -3.01 % | $ 2.02 B | ||
|
Quest Diagnostics Incorporated
DGX
|
287 M | $ 175.05 | 0.34 % | $ 19.4 B | ||
|
Biodesix
BDSX
|
2.19 M | $ 8.2 | 50.18 % | $ 1.06 B | ||
|
Organovo Holdings
ONVO
|
1.64 M | - | -2.3 % | $ 19.4 M | ||
|
Laboratory Corporation of America Holdings
LH
|
876 M | $ 249.91 | -0.75 % | $ 21 B | ||
|
ICON Public Limited Company
ICLR
|
173 M | $ 180.43 | -0.52 % | $ 14.9 B | ||
|
IDEXX Laboratories
IDXX
|
114 M | $ 722.17 | 1.24 % | $ 59.6 B |